- Home
- ZNTL vs RFI Comparison
ZNTL vs RFI Comparison
Compare ZNTL & RFI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZNTL
- RFI
- Stock Information
- Founded
- ZNTL 2014
- RFI 1992
- Country
- ZNTL United States
- RFI United States
- Employees
- ZNTL N/A
- RFI N/A
- Industry
- ZNTL Biotechnology: Pharmaceutical Preparations
- RFI Investment Managers
- Sector
- ZNTL Health Care
- RFI Finance
- Exchange
- ZNTL Nasdaq
- RFI Nasdaq
- Market Cap
- ZNTL 238.2M
- RFI 344.7M
- IPO Year
- ZNTL 2020
- RFI N/A
- Fundamental
- Price
- ZNTL $3.12
- RFI $12.73
- Analyst Decision
- ZNTL Buy
- RFI
- Analyst Count
- ZNTL 7
- RFI 0
- Target Price
- ZNTL $10.86
- RFI N/A
- AVG Volume (30 Days)
- ZNTL 1.2M
- RFI 69.8K
- Earning Date
- ZNTL 11-04-2024
- RFI 01-01-0001
- Dividend Yield
- ZNTL N/A
- RFI 8.25%
- EPS Growth
- ZNTL N/A
- RFI N/A
- EPS
- ZNTL N/A
- RFI N/A
- Revenue
- ZNTL $40,560,000.00
- RFI N/A
- Revenue This Year
- ZNTL N/A
- RFI N/A
- Revenue Next Year
- ZNTL N/A
- RFI N/A
- P/E Ratio
- ZNTL N/A
- RFI N/A
- Revenue Growth
- ZNTL N/A
- RFI N/A
- 52 Week Low
- ZNTL $2.83
- RFI $9.62
- 52 Week High
- ZNTL $18.24
- RFI $12.52
- Technical
- Relative Strength Index (RSI)
- ZNTL 44.34
- RFI 44.70
- Support Level
- ZNTL $2.92
- RFI $12.88
- Resistance Level
- ZNTL $3.23
- RFI $13.14
- Average True Range (ATR)
- ZNTL 0.17
- RFI 0.17
- MACD
- ZNTL 0.00
- RFI -0.02
- Stochastic Oscillator
- ZNTL 38.33
- RFI 21.74
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses a drug discovery engine, which it refers to as an Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. It has two lead product candidates under pipeline: ZN-c5, for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer; and ZN-c3, for the treatment of advanced solid tumors as monotherapy and ovarian cancer.
About RFI Cohen & Steers Total Return Realty Fund Inc.
Cohen & Steers Total Return Realty Fund Inc is a diversified, closed-end management investment company. Its investment objective is to achieve a high total return through investment in real estate securities. The Fund invests majority of its total assets in the equity securities of real estate companies under normal circumstances, which includes common shares, REITs, rights or warrants, convertible securities, and preferred shares.